ANTI-INFLAMMATORY EFFECTS OF ^{64}ZN-ASPARTATE IS ACCOMPANIED BY COGNITIVE IMPROVEMENTS IN RATS WITH Aβ$_{1-40}$-INDUCED ALZHEIMER DISEASE

Max Temnik[1], Mariia Rudyk[2*], Alexandr Balakin[1], Sergey Gurin[1], Taisa Dovbynchuk[2], Roman Byshovets[3], Nataliia Dzubenko[4], Ganna Tolstanova[4], Larysa Skivka[2]

[1] Physical Chemistry, Vector Vitale, North Miami Beach, USA

[2] Educational and Scientific Centre "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv, 2, Hlushkova Avenue, Kyiv 03022, Ukraine

[3] Department of Internal Diseases, Bogomolets National Medical University, 13, Shevchenko Blvd., Kyiv 01004, Ukraine

[4] Educational and Scientific Institute of High Technologies, Taras Shevchenko University of Kyiv, 4g, Hlushkova Avenue, Kyiv 03022, Ukraine.

* Corresponding author: Mariia Rudyk

Graphical abstract

Abstract

Alzheimer disease (AD) is a debilitating progressive dementia, whose pathophysiology remains poorly explored. Chronic inflammation is now widely accepted as one of the key features of AD pathogenesis. Because of this, anti-inflammatory preparations are considered as putative disease modifying agents. A new compound of zinc aspartate with enriched light atoms ^{64}Zn (^{64}Zn-asp) was evaluated as a possible anti-AD agent using $A\beta_{1-40}$-induced AD model. Intrahippocampal $A\beta_{1-40}$ injection resulted in pronounced neuroinflammation, as was evidenced by increased phagocytic activity, augmented reactive oxygen species generation, and up-regulated CD86 and CD206 expression by microglia. In rats with $A\beta_{1-40}$-induced AD, persistent systemic inflammation was also registered, as was ascertained by significantly increased white blood cell-based inflammatory indices and development of anemia of inflammation. Neuro- and systemic inflammation in rats was accompanied by hippocampal dopamine neuron loss, as well as by impairment of short-term and remote spatial memory and cognitive flexibility. Intravenous ^{64}Zn-asp administration rats with AD was associated with returning all microglia indicators to normal range. All aforementioned features of systemic inflammation were not observed in these animals. Anti-inflammatory ^{64}Zn-asp effect was strongly correlated with improvement of short-term spatial memory and cognitive flexibility, and moderately - with betterment of remote spatial memory. These results demonstrated that i.v. ^{64}Zn-asp administration could reverse the inflammatory and, as a result, cognitive effects of intra-hippocampal $A\beta_{1-40}$ in rats. Therefore, its use may be a viable approach in the complex therapeutic strategy for AD.

Key words: Alzheimer disease, stable light isotope enriched zinc aspartate, anti-inflammatory agent, inflammation, neuroinflammation, cognitive improvement.

1. Introduction

Alzheimer's disease (AD) is the most prevalent type of dementia, which is defined as slowly progressive neurodegenerative disease associated with neuronal death, memory deficits and cognitive impairment [1, 2]. Considering the rapid increase of the global ageing population, the age-related disorders, especially AD, are an earnest threat to the public health. In the US, the number of AD patients is expected to grow to 13.8 million by 2060 [3; 4]. In Europe, based on current predictions, the population in 2080 will be 520 million with 13.7 million patients with AD [5].

There are no effective disease-modifying drugs for AD treatment, mostly because the underlying causes of sporadic disease remain incompletely understood. Key AD pathological features include the accumulation of extracellular amyloid β (Aβ) plaques and intraneuronal neurofibrillary tangles of phosphorylated tau protein (tau/NFT) [6]. Four FDA approved preparations: acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and a N-methyl D-aspartate receptor ion channel antagonist memantine do not provide a cure, but rather limit the symptoms of the disease. Monoclonal antibodies that target Aβ plaques (aducanumab, lecanemab and donanemab) have shown potential in reducing their deposition and slowing cognitive decline in clinical trials. However, the use of these drugs is associated with adverse immune responses. [7, 8, 9]. Considering a serious demand for disease-modifying drugs, main efforts are focused on finding new therapeutic targets in the context of available knowledge concerning AD pathogenesis. According to current hypotheses, amyloid cascade [10], oxidative stress [11], and cerebral amyloid angiopathy [12] are regarded main pathogenesis components.

Lately, inflammation (peripheral and central or neuroinflammation) is considered a novel AD feature and potential therapeutic target [13, 14, 15]. The use of non-steroidal anti-inflammatory drugs have not been successful in treating AD [16]. Other drugs targeting inflammation resolution

and restoration of microglia phagocytic function for effective Aβ clearance are presently being tested (TNF-α blocker etanercept, COX-1 inhibitor CSP-1103 etc.) with promising results [8].

Inflammation is associated with a range of biochemical responses, which in turn provokes alterations in levels of acute phase reactants including zinc concentration [17]. Zinc is the second most plentiful trace element in the human central nervous system. The brain is known to have significant zinc content, particularly in specific synaptic vesicles of glutamatergic neurons. Zinc homeostasis is highly important for healthy brain function, since this trace element is a structural component in ~ 70% of proteins. Zinc is involved in the functioning of more than 300 enzymes, 2000 transcription factors, and is crucial for numerous neurobiological processes [18]. Zinc dyshomeostasis is involved in the pathophysiology of chronic diseases related to aging, since the intestinal zinc absorption is declined with age [19]. Zinc dysregulation violates neural networks and supports pathological events, potentially leading to neurodegeneration. Moreover, emerging evidence demonstrated that zinc is involved in key aspects of AD pathogenesis: Aβ plaques and tau/NFT formation [20]. All these facts stipulated formulating zinc dyshomeostasis hypothesis of AD, which is closely related to inflammation [21].

Zinc levels have been extensively investigated in different brain regions, as well as in serum and plasma in patients with AD and in animal models of the disease. Studies concerning serum/plasma zinc levels in AD patients exhibited contradictory results, showing significant reductions [22], substantial increase [23] or no difference [24] as compared to healthy persons. There is also no consensus about the zinc content in AD brains. Post-mortem analyses of AD brains showed both decreased zinc levels in brain tissue [25] and significantly increased zinc levels in the hippocampus and amygdala [26] as compared to healthy controls. Nevertheless, it is commonly accepted that pathological changes glutamatergic activation in AD leads to synaptic zinc dyshomeostasis, which in turn causes microglia activation. Microglia has recently been recognized as an important contributor in AD pathogenesis. Microglia is a population of tissue-resident macrophages in the brain, which are responsible for sustaining, nourishing, and immune surveillance [27]. However, pro-inflammatory disease-associated microglia (DAM) drives neuroinflammation, which contributes to AD initiation/progression and severity, and microglia-targeted therapeutics could be promising in mitigating neuroinflammatory responses [28]. Zinc plays important roles in microglia activation and can cause either pro-inflammatory (AD promoting) or anti-inflammatory metabolic shift of these cells depending on their initial activation state [29, 30].

Since zinc dyshomeostasis is involved in AD and associated with inflammation, numerous dietary zinc supplementation studies were performed in mice and humans with no clear consensus on the effects of zinc supplementation in AD pathology in animal models [24]. However, improvements in cognition and memory in AD patients following dietary zinc supplementation were reported in a few clinical trials [31, 32]. In all these studies, isotopically natural zinc compounds were used. Zinc has five stable isotopes (^{64}Zn, ^{66}Zn, ^{67}Zn, ^{68}Zn, and ^{70}Zn) with average natural abundances of 48.6, 27.9, 4.1, 18.8, and 0.6% respectively. Since the isotopes ^{64}Zn and ^{66}Zn are the most abundant, the ratio of ^{66}Zn/^{64}Zn expressed as δ^{66}Zn is commonly used for characterizing Zn isotopic compositions in mammalian tissues [33]. One of the features of zinc homeostasis in healthy brain is the prevalence of light isotope ^{64}Zn (δ^{66}Zn < 1). This predominance is explained by the peculiarities of chemical bonds of zinc in its compounds in different tissues. Zinc bonds with oxygen- (sulfate, phosphate, lactate) and nitrogen-containing motifs (histidine) is tight and facilitate heavy isotope, whereas bonds with sulfur (cysteine, methionine) favor light zinc isotope. In healthy brain, zinc is mostly bound to cysteine within metallothioneins [34, 35]. According to current hypothesis, heavy zinc isotope accumulates through time in the human body, and δ^{66}Zn increases with age [33, 36]. This re-distribution of zinc isotopes in the brain is manifested in neurological diseases associated with protein misfolding [37]. Namely, in AD brains, particularly in amyloid-β (Aβ) plaques, heavy zinc isotope binds to the histidine residues in the N-terminal hydrophilic region of the Aβ peptide.

In this study, we used novel zinc-based drug substance, KLS-1, which is zinc aspartate enriched with light isotope ^{64}Zn to 99.2% atomic fraction of total zinc (as opposed to the natural

isotopic ratio of 48.6% used in zinc supplements). In our previous experiments, KLS-1 exhibited more potent biological activity as compared to Zn aspartate with natural isotope distribution [38, 39].

Usually, zinc supplements are given orally with weak therapeutic efficacy. Aforementioned decline of intestinal zinc absorption with age could be one of the reasons, and parenteral supplementation could eliminate this drawback [40, 41, 42]. To our best knowledge, this is a first report concerning the impact of intravenous (i.v.) administration of isotopically modified zinc in animal model of AD. The aim of this study was to assess the effect of ^{64}Zn aspartate (KLS-1) i.v. administration on local and systemic inflammation, as well as on cognitive parameters in rats with $A\beta_{1-40}$-induced AD.

2. Materials and Methods

2.1. Test agent

^{64}Zn aspartate (^{64}Zn-asp), an investigational new complex of zinc aspartate containing a Zn atom enriched in light isotope ^{64}Zn to >99% atomic fraction of total zinc. (Fig. 1), was used as a therapeutic test agent. Molecular formula: $C_8H_{12}O_8N_2{}^{64}Zn$.


Fig. 1. Schematic representation of ^{64}Zn-Aspartate structure.

2.2. Animals, study design, and behavioral testing.

Study design is provided in Fig.2. Fourteen-month-old male Wistar rats (300-500 g) were utilized in the study. Animals were held in the vivarium of the ESC "Institute of Biology and Medicine" of Taras Shevchenko National University of Kyiv in standard conditions (temperature 20 ± 2°C, 12 h light/dark cycle with free access to water and food). Each rat was kept in a separate cage. The animal maintenance protocol was approved by the University's Bioethics Committee in accordance with the Animal Protection Act (protocol No 4, 10.10.2022). All animal studies were performed in accordance with the norms established by the Law of Ukraine No. 3447-IV "On the Protection of Animals from Cruelty", and in accordance with the standards of the Convention on Bioethics of the Council of Europe "European Convention for the Protection of Vertebrate Animals Used in Experimental and Other Scientific Research goals" (1997), general ethical principles of work with experimental animals approved by the First National Congress on Bioethics of Ukraine (September 2001) and other international agreements and national legislation in this field. Before the experiment, the animals were randomly distributed into 4 groups using the "RAND ()" function in Microsoft Excel: I (n=8) – intact animals, which did not undergo any manipulations (intact); II (n=8) – sham-operated (sham) animals; III (n=8) – rats with $A\beta_{1-40}$ induced AD (AD), and AD animals revieved i.v. ^{64}Zn-asp (n=8). $A\beta_{1-40}$ (Cayman Chemical, USA) solution was dissolved in ddH$_2$O at a concentration of 15 μmol/L and incubated at 37°C for 24 h before use. Surgery and $A\beta_{1-40}$ AD induction were performed as described previously [43-45]. Rats were anesthetized with a mixture of ketamine (75 mg/kg, Sigma, USA) and 2% xylazine (100 μL/rat, Alfasan International B.V., The Netherlands) i.p. in the volume of 1 mL. After this, rats were placed in a stereotaxic apparatus (SEJ-4, Ukraine), and were scalped from the point of intersection of the sagittal suture with the bregma (zero point): 2 mm distally, 2 mm laterally, and 3.5 mm deep, and a burr hole was made with an

injection needle directly into the hippocampus. Then, rats were injected unilaterally into hippocampus with aggregated $A\beta_{1-40}$. The volume of the suspension was 10 µL per rat, infusion was made for 5 minutes at a rate of 0.5 µL/min (every 15 s). After $A\beta$ infusion, the tip of the microinjector stayed in the brain tissue for 4 min. Sequentially, the microinjector was removed, and the soft tissues of the head were sutured. The sham group received intra-hippocampal injection of 10 µL of sterile ddH2O [45]. Rats from groups IV received 10 daily i.v. (into the lateral tail vein) ^{64}Zn-asp injections at a dose of 1.5 mg/kg starting from the Day 17.

Day 5 short-term spatial memory assessment	Day 10 Aβ surgery	Day 18 – Day 27 i.v. ^{64}Zn-aspartate administration	Day 32 short-term spatial memory assessment	Flow cytometry: • Phagocytosis assay; • ROS assay; • CD86 and CD206 expression; • Hemogram.

Day 37 Autopsy

| Day 1 – Day 4 habituation, and Barnes Maze training sessions	Day 9 remote spatial memory assessment	Day 17 remote spatial memory assessment	Day 28 – Day 31 post-surgery Barnes Maze training sessions	Day 36 remote spatial memory assessment	TH-positive neuron assessment in hippocampal area

Fig. 2. Study design

To evaluate hippocampal-dependent learning, short-term and long-term (remote) spatial memory, the Barnes maze was used [46]. The testing was aimed in estimating the animal ability to learn and memorize the location of the escape box using visual hints on the walls around the device. Barnes maze consisted of a rotative platform (120 cm in diameter), raised 90 cm above the floor. The platform contained 16 escape holes (each is 10 cm in diameter) located along its periphery. Spatial hints (black triangles and paired black stripes) were placed on the walls of the room to serve as visual cues for navigation and spatial orientation during the Barnes maze test. A dark escape box with a standard animal filler was put under the target hole. Each animal was assigned its own target escape box number. The habituation trial and training phase consisted of a set of four daily training sessions (each with four trials per day with 15-min intertrial interval). Just before each trial, the animals were placed inside a dark starting cylinder positioned at the center of the platform for 10 seconds. Sequentially, the cylinder was removed, and animals were permitted to explore the maze and holes for 2-3 minutes, or until they found the target hole. If the animal failed to find the box within this time period, it was guided lightly to the target hole. On Day 5 (24 hours after the last training), the short-term spatial memory was tested, and on Day 9 (5th day after the last training), after the memory consolidation period, the remote memory was tested: the escape box was removed from the maze, and the entrance to the escape box was closed. The rats were given 90 seconds of free movement across the platform for finding the entrance to its own target hole (where the entrance to the escape box was previously located), based on previously gained skills. On Day 10, the $A\beta_{1-40}$ induction surgery was performed as described above. On Day 17 (7 days after the surgery) remote spatial memory was tested again. From Day 28 to Day 31 (18 to 21 days after the surgery), the animals were retrained (the escape box for each animal was relocated), and post-surgery short-term and remote memory were assessed on Day 32 and Day 36 after the intrahippocampal $A\beta$ infusion respectively. The test endpoints were (in seconds): 1) escape latency - the time required for an animal to find the

entrance to the target escape box from when the animal is released from the starting cylinder (characterizes spatial learning and spatial memory - related to the function of the hippocampus) – t1; 2) the time spent near the entrance to closed target hole (characterizes cognitive flexibility - related to the function of the frontal cortex of the brain [47] – t2. In addition, $\Delta t1_{5-32}$ and $\Delta t2_{5-32}$ were calculated for assessing changes in short-term spatial memory and cognitive flexibility in the course of AD and after the treatment with ^{64}Zn-asp. $\Delta t1_{9-17}$, $\Delta t1_{9-36}$, $\Delta t2_{9-17}$ and $\Delta t2_{9-36}$ were also calculated for assessing changes in remote spatial memory and cognitive flexibility. On Day 37, rats were sacrificed, and biological materials (brain tissue and blood) were collected for immunohistochemistry, ELISA, hematological and immunological assays.

2.2. Immunohistochemistry.

Dopaminergic neuron (DN) degeneration in hippocampal area was evaluated by immunohistochemical staining of tyrosine hydroxylase (TH)-positive neurons (Walsh et al., 2011). Profoundly anaesthetized rats were transcardially perfused with ice-cold heparinized saline (5000 U/L), and then with 4 % paraformaldehyde. After this, animal brains were gently excised and fixed in 4 % paraformaldehyde overnight. For immunohistochemical staining 5 μm-thick sections were used. Endogenous peroxidase activity was quenched with blocking solution (Dako, EnVision Flex, DM821). Nonspecific secondary antibody binding was blocked with a 4 % solution of milk powder in Tris-buffered saline (TBS) with 0.2 % Triton X-100. First, tissue sections were incubated with primary antibody (dilution 1:200 in TBS with 0.2 % Triton X-100) (Millipore, AB152) at 4 ∘C overnight. After this, the sections were incubated with secondary antibody (biotinylated anti-rabbit, 1:200) for 60 min, and then - with a streptavidin–biotin horseradish peroxidase solution. Immunolabelling was visualized using 0.5 % solution of diaminobenzidine tetrahydrochloride in TBS containing 30 % hydrogen peroxide (Dako, EnVision). TH-positive staining intensity was assessed using a Quantitative Scoring Methods, considering the number of positive (stained) cells and staining intensity [48]. The results were counted by multiplying the percentage of positive cells (P) by the intensity (I) and presented as a quick estimate (Q): $Q = P \times I$.

2.3. Hematological assay

EDTA anti-coagulated blood was used in hematological investigations. The hematological indices were determined using an automated hematology analyzer "Particle counter model PCE 210" (ERMA, Japan), adapted for the study of blood cells of rats and mice. Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), platelet to neutrophil ratio (PNR), platelet to monocyte ratio (PMR), neutrophil to monocyte ratio (NMR), systemic immune inflammation index (SII), and a mean platelet volume (MPV)/ platelet count (PLT) were calculated using the following formulas: NLR = absolute neutrophil count (ANC)/absolute lymphocyte count (ALC); LMR = (ALC)/absolute monocyte count (AMC); PLR = absolute platelet count (APC)/ALC; PNR = APC/ANC; PMR = APC/AMC; NMR = ANC/AMC; SII = (ANC × APC)/ALC [49]. Additionally, a mean platelet volume (MPV)/ platelet count (PLT) was calculated.

2.4. Microglia/macrophage cell isolation

Complex population of microglia/macrophage cells was isolated as described by Frank et al. [50] with slight modifications [50, 51]. Whole brain was lodged in cold Dulbecco's PBS (DPBS) supplemented with 0.2% glucose and minced into 1–2 mm pieces using scissors. After this, tissue pieces were carefully disintegrated in DPBS using a tissue homogenizer. For separating cell aggregates, homogenate was filtered through a 40 μM cell strainer (BD Biosciences Discovery, USA), and cell suspension was then centrifuged at 350 g for 10 min. Cells were then mixed with 1 ml of 70% isotonic Percoll (Sigma). Two milliliters of 50% isotonic Percoll was carefully layered on top of the 70% layer followed by 1 ml PBS layering on the top of the 50% Percoll layer. prepared mixture was then centrifuged at 1200 g for 45 min. The layer enriched with microglia/macrophages at the interface between the 70 and 50% isotonic Percoll phases were isolated. Cell viability was assessed using the trypan blue exclusion test. The proportion of viable cells was ≥ 95%. FITC-conjugated mouse anti-rat CD11b antibodies (BD Pharmingen, USA) and PE-conjugated mouse anti-

rat CD45 (BD Pharmingen, USA) were then used for assessing cell purity. CD11b+CD45+ cell proportion was ≥ 88%.

2.5. *Flow cytometry*

Flow cytometry was used for assessing polarized activation of phagocytes: microglia/macrophage cells and peripheral blood monocytes (Mo) and granulocytes (Gr), which was characterized by phagocytic activity, reactive oxygen species generation and expression of phenotypic markers CD206 and CD86 as described earlier [45, 51]. In the phagocytic activity assay, FITC-labeled thermally inactivated cells of *Staphylococcus aureus* Cowan I (collection of the Department of Microbiology and Immunology, ESC "Institute of Biology and Medicine" of Taras Shevchenko National University of Kyiv) were used as an endocytosis object. Isolated microglia/macrophage cells or animal blood samples were incubated with bacterial cells for 30 min at 37°C. Phagocytosis was stopped using a 'stop' solution (PBS with 0.02% EDTA and 0.04% paraformaldehyde). Data are presented as the phagocytosis percentage (PP) and phagocytosis index (PI) (the mean fluorescence intensity, MFI). The oxidative metabolism was tested using 2′7′-dichlorodihydrofluorescein diacetate (H2DCFDA, Invitrogen). Data are presented as percentage of ROS-producing cells and ROS generation level (the mean fluorescence intensity, MFI). FITC-labeled anti-CD86, and phycoerythrin (PE)-labeled anti-CD206 antibodies (Becton Dickinson, Pharmingen, USA) were used for phagocyte phenotyping. Results were assessed using DxFlex flow cytometer and analyzed using Kaluza C Analysis Software (Beckman Coulter, Inc., USA). Gr and Mo were gated according to forward and side scatter.

2.6. *Statistical analysis*

Statistical analysis was conducted using the Statistica 12.0 package. First, data was examined for normality of distribution using the Shapiro-Wilk test [52]. Normally distributed variables are expressed as mean ± SD. Nonnormally distributed variables are expressed as the median and interquartile range (IQR). Statistical differences were calculated using ANOVA with Tukey's post-hoc test for multiple comparisons of variables with a normal distribution, and Kruskal-Wallis's test for multiple comparisons of variables with a non-normal distribution [53]. Spearman correlation test was used to determine the statistical relationships between the short-term and remote spatial memory parameters and inflammation biomarker values. Differences were considered significant at $p < 0.05$.

Results

3.1. *Treatment with ^{64}Zn-asp abrogates pro-inflammatory metabolic polarization of microglia/macrophage population in rats with Aβ$_{1-40}$-induced AD*

In our experiments, complex population of microglia (MG)/border-associated macrophages (BAM) were examined. In healthy brain of intact animals, yolk sac-derived resident microglial cells (MG) prevail with minor fraction of border-associated macrophages (BAM). Aging in human and rodents is associated with an increase in the proportion of BAM in the complex population of brain phagocytes, and with their slight pro-inflammatory shift caused by age-associated low-grade inflammation [54]. In addition, in neurodegeneration, BAM fraction can increase as a result of blood monocytes recruitment [55]. Phagocyte polarized activation was assessed by key functional characteristics, which allow to evaluate their metabolic shift (pro- or anti-inflammatory): phagocytic activity, oxidative metabolism and expression of phenotypic markers CD86 and CD206 [56]. It necessary to note, that MG/BAM population in sham-operated animals was in activated state, as indicated by increased phagocytic activity (which was characterized by PI values) as compared to intact animals (Fig.3B). ROS generation was also higher in MG/BAM from rats in sham group than in intact animals (Fig.3C). This can be attributed to residual low-grade inflammation after the placebo neurosurgery. Nevertheless, proportion of phagocytizing MG/BAM cells in sham-operated animals was even lower than that in intact animals (Fig.3A), indicating the resolution of post-surgery meta-inflammation and returning MG/BAM cells to resting state. Fractions of CD86+ (Fig.3D) cells and CD206+ cells (Fig.3F), as well as expression levels of these phenotypic markers (Fig.3E and G

correspondingly) in MG/BA population of sham-operated rats did not differ significantly from those in intact animals, additionally evidencing a lack of pronounced inflammation.

MG/BAM population in rats with $A\beta_{1-40}$-induced AD had all the hallmarks of activated and pro-inflammatory shifted cells. Median value of PP (proportion of phagocytizing cells) was 2.6 times higher as compared to intact rats and almost 10 times higher than in sham-operated group (Fig.3A). Median value of PI in AD rats was 6 times higher as compared with intact animals and 3 times higher than in rats from sham group (Fig.3B). Levels of ROS production by MG/BAM in animals with AD were 2.5 times higher as compared to those in sham-operated rats and 5 times higher than in intact animals (Fig.3C). Our next parameter, CD86 is one of the co-stimulatory molecules, which is constitutively expressed by all tissue-resident macrophages including MG. Overexpression of CD86 is associated with pro-inflammatory shift of macrophage profile. In our experiments, proportions of CD86+ MG/BAM did not differ significantly in all animal groups (Fig.3D), although median value of this parameter in rats with $A\beta_{1-40}$-induced AD was almost twice as high as in control animals. CD86 expression levels in AD animals were 3 times higher as compared to control rats (Fig.3E). Our next indicator - CD206 - is a key phenotypic marker differentiating MG and BAM, since resting MG is CD206 negative, reactive microglia (which is involved in neuroinflammation and AD pathogenesis) is CD206^{low}, whereas BAM are CD206^{high} [57, 58]. Median value of the proportion of CD206+ cells in MG/BAM population from rats with AD was three times higher than that in control animals indicating increase of BAM fraction and/or resident MG activation (Fig.3F). Median value of CD206 expression level in rats with $A\beta_{1-40}$-induced AD was nearly 10 times higher than in control animals (Fig.3G).

Fig. 3. Effect of i.v. administration with Zn^{64}-asp on metabolic characteristics of microglia/macrophages in rats with $A\beta_{1-40}$-induced AD. A – phagocytosis percentage; B – phagocytosis index; C – ROS generation; D – fraction of CD86-positive cells; E – CD86 expression level; F - fraction of CD206-positive cells; G – CD206 expression level. Data are presented as medians and IQR. Data from different animal groups were compared using Kruskal-Wallis's test. ***a*** - p ≤ 0.05 as compared to intact animals, ***b*** - p ≤ 0.05 as compared to sham-operated animals; ***c*** - p ≤ 0.05 as compared to animals with $A\beta_{1-40}$-induced AD.

Treatment rats with $A\beta_{1-40}$-induced AD with ^{64}Zn-asp returned all MG/BAM indicators to normal range. PP values of MG/BAM in this group were at the level of intact animals (Fig.3A). Phagocytic activity (Fig.3B) and ROS generation (Fig.3C) values were also the same as in intact rats. Of special note is low individual variability of these indicators in rats with AD treated with ^{64}Zn-asp, which provided the high significance of differences in comparison with untreated rats with AD. As mentioned above, percentage of CD86+ cells in MG/BAM population was similar in all animal groups. Nevertheless, median value of this indicator in rats with AD treated with ^{64}Zn-asp was 4 times lower than that in untreated AD animals, and was even lower than in intact animals (Fig.3D). CD86 expression levels in rats with $A\beta_{1-40}$-induced AD received i.v. zinc administration was 5 times lower as compared to values of untreated animals with AD and was the same as in sham-operated rats (Fig.3E). Percentage of CD206+ cells in MG/BAM population in AD rats received i.v. zinc was 5 times lower than in untreated animals and did not differ from that in sham-operated rats (Fig.3F).

Median value of CD206 expression level on rats treated with ^{64}Zn-asp was 8 times lower than in untreated AD animals and did not differ from those in control groups (Fig.3G).

3.2. ^{64}Zn-asp mitigates systemic inflammation in rats with Aβ$_{1-40}$-induced AD

Pro-inflammatory MG/BAM activation in rats with Aβ$_{1-40}$-induced AD was also accompanied by persistent systemic inflammation, as ascertained by commonly accepted hematological markers [59]: apparent leukocytosis (WBC count was twice higher as compared to intact animals, and 1.3 times higher than in sham-operated rats) coupled with significant increase of absolute (by 4.7 times as compared to intact rats and 3 times – to sham-operated) and relative (by 2 times) Gr (neutrophil, Neu) count (Table 1). In AD rats given the ^{64}Zn-asp, total WBC and Neu count were within the normal range. Monocytopenia in rats with Aβ$_{1-40}$-induced AD, probably caused by Mo recruiting into the inflamed brain areas [60, 61], was another marker of systemic inflammation. In animals with AD received ^{64}Zn-asp, monocytopenia was found to be absent. It should be noted that slight leukocytosis coupled with increased absolute lymphocyte (Ly) count, which were observed in sham-operated animals, can be attributed to the resolution of post-surgical low-grade inflammation.

Additionally, we also calculated commonly used systemic inflammatory indices based on the composition ratio of blood cell counts: NLR, LMR, PLR, PNR, PMR, NMR, SII and MPV/PLT (Table 2).

NLR values in rats with Aβ$_{1-40}$-induced AD were ~5 times higher, LMR values - more than two times higher, NMR values - ~17 times higher, and SII values - ~9 times higher than corresponding values in control animals. This additionally indicates disproportion in Neu, Mo and Ly count and proves persistent systemic inflammation, which is characteristic for AD patients. In animals with AD given i.v. ^{64}Zn-asp, all aforementioned indices of systemic inflammation did not exceed those in control groups.

Table 1

WBC count with differential in rats with Aβ$_{1-40}$-induced Alzheimer disease given i.v. ^{64}Zn-asp

	Intact animals, n=8	Sham-operated animals, n=8	Aβ$_{1-40}$-induced AD, n=8	Aβ$_{1-40}$-induced AD + ^{64}Zn-asp, n=8
WBC, x 10^3/μl	12.4 [10.5; 14.9]	19.3 [17; 24] [a]	24.3 [23.9; 24.7] [ab]	13.7 [10.1; 20] [c]
Ly, x 10^3/μl	5.3 ± 2.1	10.5 ± 4.7	4.5 ± 0.2	6.2 ± 2.8
Mo, x 10^3/μl	1.5 ± 0.5	2.2 ± 0.4	0.2 ± 0.05 [ab]	1.3 ± 0.6 [c]
Gr, x 10^3/μl	4.2 ± 1.2	6.7 ± 2.2	19.6 ± 0.7 [ab]	6.2 ± 2.4 [c]
PLT, x 10^3/μl	225.5 ± 28.7	397.7 ± 93 [a]	401.6 ± 29.4 [a]	255 ± 37.5 [bc]
Ly, %	60.0 ± 12.8	53.2 ± 4.7	18.3 ± 0.5 [ab]	50.6 ± 5.9 [c]
Mo, %	8.4 ± 2.8	10.8 ± 3.8	0.9 ± 0.2 [ab]	7.5 ± 2.5 [c]
Gr, %	39.7 ± 9.5	36 ± 4.5	80.6 ± 0.4 [ab]	41.9 ± 7.4 [c]

Note: data are presented as median and IQR or as mean ± SD. Data from different animal groups were compared using Kruskal-Wallis's test or ANOVA with Tukey post-hoc test correspondingly. [a] - p<0.05 as compared to intact animals; [b] - p<0.05 as compared to sham-operated animals; [c] - p<0.05 as compared to untreated animals with Aβ$_{1-40}$-induced AD.

Platelets (PLT) have been established as crucial regulators of inflammatory responses under different pathological conditions. PLT overactivation in the course of inflammation is followed by the development of thrombosis, atherosclerosis, and cardiovascular diseases [62]. PLT interact with Neu, Mo and Ly physically and by producing soluble mediators, and in such a way facilitate

migration and functioning of these cells [63]. In our experiments, PLT count in AD rats was the same as in sham-operated animals and 1.8 times higher than in intact animals (Table 1). Mean PLT volume (MPV) did not differ significantly in animals from different groups (data are not shown). As a result, MPV/PLT ratio values in animals from sham and AD groups were lower as compared to intact animals. MPV can indicate either PLT activation or increased number of large sized PLT without their activation. In the light of this information, decreased MPV/PLT in animals with AD might indicate aberrant PLT functionality. In rats with $A\beta_{1-40}$-induced AD given i.v. ^{64}Zn-asp, MPV/PLT values were at the level of intact animals. At the same time, PLR values in rats with AD were twice as high as in control animals. PNR values in AD group were 4.7 times higher than in intact animals and 3 times higher than in sham-operated rats. PMR values in animals with AD were ~7 times higher as compared to those in control animals. This can additionally indicate improper PLT functioning. In AD rats received ^{64}Zn-asp, all these indices were at the level of intact animals.

Table 2

Indices of systemic inflammation in rats with $A\beta_{1-40}$-induced Alzheimer disease given i.v. ^{64}Zn-asp

	Intact animals, n=8	Sham-operated animals, n=8	$A\beta_{1-40}$-induced AD, n=8	$A\beta_{1-40}$-induced AD + ^{64}Zn-asp, n=8
NLR	0.89 ± 0.4	0.68 ± 0.1[a]	4.41 ± 0.1[ab]	0.99 ± 0.1[c]
LMR	8.31 ± 2.5	5.32 ± 1.8[a]	20.46 ± 4.2[ab]	6.45 ± 2.9[c]
PLR	47.7 ± 16.3	44.3 ± 12.5	90 ± 27.7[ab]	48.4 ± 21.7[c]
PNR	4.2 ± 1.2	6.7 ± 2.2	19.6 ± 0.7[ab]	6.3 ± 3.3[c]
PMR	285.4 ± 92.4	245.5 ± 52.3	1887.5 ± 81.5[ab]	335.3 ± 87.5[c]
NMR	5.3 ± 2.5	3.6 ± 1.3[a]	90 ± 16.8[ab]	6.3 ± 3[c]
SII	199.9 ± 45.4	264.2 ± 40.7[a]	1760.9 ± 225.4[ab]	250.8 ± 40.9[c]
MPV/PLT	0.06 ± 0.01	0.03 ± 0.01[a]	0.03 ± 0.01[a]	0.05 ± 0.02[c]

Data are presented as mean ± SD. Data from different animal groups were compared using ANOVA with Tukey post-hoc test. [a] - p<0.05 as compared to intact animals; [b] - p<0.05 as compared to sham-operated animals; [c] - p<0.05 as compared to untreated animals with $A\beta_{1-40}$-induced AD.

Additional sign of persistent systemic inflammation in our study was anemia of inflammation or chronic disease (AICD), which is characteristic for AD [64]. The presence of AICD was ascertained by corresponding red blood cell (RBC) indices (Table 3). Earlier, we registered reproducing AICD in $A\beta_{1-40}$-induced AD model [45]. In our current study, RBC count in AD rats was slightly lower than those in control animals (Table 3).

Table 3

Red blood cell indices in rats with $A\beta_{1-40}$-induced Alzheimer disease given i.v. ^{64}Zn-asp

	Intact animals, n=8	Sham-operated animals, n=8	$A\beta_{1-40}$-induced AD, n=8	$A\beta_{1-40}$-induced AD + ^{64}Zn-asp, n=8
RBC 10^6/µl	7.3 ± 0.9	6.8 ± 0.4	6 ± 2	7 ± 0.3
Hgb, g/dl	15.8 ± 2.1	15.5 ± 1.4	27.1 ± 2.5[ab]	14.1 ± 1.1[c]
HCT, %	38.5 ± 4.6	34.9 ± 2.6	35.6 ± 9.8	35.9 ± 1[c]
MCV, fl	52.9 ± 2.7	50.9 ± 1	58.4 ± 5	51 ± 1[c]
MCH, pg	23 ± 1.3	21.9 ± 1	44.4 ± 3.2[ab]	20 ± 0.7[c]
MCHC, g/dl	43 ± 1.8	40.9 ± 1.5	74.2 ± 3.2[ab]	39.2 ± 2.2[c]
RDW, %	15.8 ± 0.6	16 ± 2.5	24.4 ± 4.4[ab]	16.8 ± 1.4[c]

Note: data are presented as mean ± SD. Data from different animal groups were compared using ANOVA with Tukey post-hoc test. [a] - p<0.05 as compared to intact animals; [b] - p<0.05 as compared to sham-operated animals; [c] - p<0.05 as compared to untreated animals with $A\beta_{1-40}$-induced AD.

Hb level values in animals with Aβ$_{1-40}$-induced AD were 1.7 times higher as compared to those in control animals. The values of mean corpuscular hemoglobin (MHC) and the concentration of hemoglobin in RBC (MCHC) in AD rats were also higher than in control groups by 2 and 1.8 times correspondingly. Mean corpuscular volume (MCV) values did not differed significantly in animals from different groups, whereas RBC distribution width (RDW) values in animals from AD group were 1.5 times higher than in control groups. In rats with Aβ$_{1-40}$-induced AD given i.v. ^{64}Zn-asp, all aforementioned measures did not differ from those in intact animals.

3.3. Anti-inflammatory effects of ^{64}Zn-asp correlate with spatial memory improvements, and is associated with reduced DN loss in rats with Aβ1-40-induced AD.

Pro-inflammatory state of MG/BAM, as well as systemic inflammation in rats with Aβ$_{1-40}$-induced AD was associated with spatial learning/memory impairments, and DN loss.

Immunohistochemical analysis using TH as DN protein marker and a quick estimate Q for quantitative assessment, which are considered the gold standard for rodent models of neurodegenerative diseases [65] were used for evaluating hippocampal DN loss. TH expression level in hippocampal preparations of intact animals, assessed by Q values, was 6.0±0.0 points (Fig.4A). In sham group, the staining intensity of TH-positive cells did not differ significantly from that of intact rats and Q value was 7.0±1.7 points (Fig.4B). In AD rats, TH expression level was 2.3±1.5 points, which is almost three times less than in animals from control group and indicates DN loss (Fig.4C). I.v. administration ^{64}Zn-asp resulted in an increase in the Q value to 4.0±2.0 points (Fig.4D), to a greater extent due to an increase in the cell staining intensity, rather than their number, indicating protective effect of the preparation on hippocampal DA functions.


Fig. 4. Representative images of immunostaining of the TH-positive neurons (brown) in hippocampal area of the intact (A), sham-operated (B), AD (C) and AD+Zn experimental groups (Quick scores (Q) was calculated by multiplying the percentage of positive cells (P) by the intensity (I)), magnification x400. Data are presented as mean ± SD. Data from intact, sham-operated, AD and AD+Zn animals were compared using ANOVA with Tukey post-hoc test. * – p < 0.05 as compared to intact animals; # – p < 0.05 as compared to sham-operated animals.

Fig. 5. The effect of i.v. administration with ^{64}Zn-asp on behavioral characteristics of rats with Aβ$_{1-40}$-induced AD in the Barnes Maze Test. A, B – short-term spatial memory; C, D – short-term cognitive flexibility; E, F, G and H – remote spatial memory, I, J, K and L - remote cognitive flexibility. n=8 in each animal group. Data are presented as medians and IQR. Data from different animal groups were compared using Kruskal-Wallis's test. a - $p < 0.05$ as compared to the corresponding value at Day 5 (Fig. A and C) or Day 9 (Fig. E): b - $p < 0.05$ as compared to the corresponding value in intact animals at the same time point; c - $p < 0.05$ as compared to corresponding value in sham-operated animals at the same time point; d - $p < 0.05$ as compared to corresponding value in untreated AD animals at the same time point.

To assess spatial learning and spatial memory, two Barnes maze training sessions were performed: at the beginning of the experiment (Days 1-4), and on Days 28-31 (18 days after the surgery in sham and AD groups) (Fig.5B). The first criterion for characterizing spatial learning and spatial memory, was short-term (working) spatial memory, which was assessed by the latency to find out the escape box (t1). The t1 values decreased over both training sessions in all animal groups, as was indicated by analogous learning curves (data are not shown). In the first probe trial (Day 5), t1 values were comparable for animals from all groups (Fig.5A). At the subsequent probe trial on Day 32 (after the second (post-surgery) training session), t1 values in animals from control groups were lower as compared to those on Day 5, as evidenced by positive values of Δt1$_{5-32}$ (Fig.5B), indicating

positive effect of repeated spatial memory training on working memory formation. In rats from AD group, median values of t1 on Day 5 and Day 32 were identical, and $\Delta t1_{5-32}$ was 10 times lower than in controls indicating deterioration of working learning and memory in these animals. In AD animals given i.v. ^{64}Zn-asp, median value of t1 on Day 32 was 1.5 times lower as compared to that on Day 5, and did not differ significantly from those in control animals. Median value of $\Delta t1_{5-32}$ was positive and 2 times higher than that in untreated AD animals, which testifies to positive effect of the preparation on spatial learning.

Next criterion, the time spent near the entrance to closed target hole (t2), characterizes short-term cognitive flexibility. The less time the animal has been near the closed entrance to the escape box, the higher its level of cognitive flexibility (frontal cortex function), i.e., the animal more rapidly recognizes that the rescue hole should be looked for elsewhere. The t2 values were comparable for animals from all groups on Day 5 (after the first training session), and decreased by 30-50% in animals from control groups after the post-surgery training session (second probe trial, Day 32) as compared with values after the first training session (Day 5) (Fig.5C), indicating positive effect of retraining on cognitive flexibility. Median values of $\Delta t2_{5-32}$ in these animals were >0 (Fig.5D). In contrast, in rats from AD group, $\Delta t2_{5-32} = -7$, indicating increase time spent near the entrance to closed target hole even after retraining and impaired cognitive flexibility as a result of the disease development. Treatment AD rats with ^{64}Zn-asp was associated with improvement of cognitive flexibility after the retraining: median value of $\Delta t2_{5-32}$ was positive and comparable to those in control animals. This can indicate positive impact of the ^{64}Zn-asp treatment on the frontal lobe function of lesioned rats.

Our next measures were associated with remote spatial memory and behavioral flexibility. At the Day 9 (5th day after the last training in the first training session), t1 values were identical in animals from all four groups (Fig.5E). At the Day 17 (13 days after the end of the first training session), a tendency to shortening t1 was observed in rats from control groups with positive $\Delta t1_{9-17}$ values (Fig.5F), indicating memory consolidation. Whereas in rats with AD, t1 values were higher at this time point as compared to values five days after the first training session. It indicates, that Aβ surgery and disease initiation held the week before, had negatively affected the remote spatial memory consolidation. Treatment with ^{64}Zn-asp did not affect this parameter in AD animals.

At the Day 36 (5 days after the second (post-surgery) training session), t1 values in intact rats significantly decreased, indicating progressive improvement of remote spatial memory after retraining. In sham-operated rats, t1 values at the Day 36 were only a little lower than those at Day 9 (Fig.5G), and were slightly higher as compared to Day 17 (Fig.5H). This could be viewed as negative consequences of the placebo surgery, which interfere with forming of remote spatial memory. In rats with AD, t1 values at Day 36 did not differ significantly from those at Day 9 and Day 17, demonstrating deterioration of the remote spatial learning and memory. In AD rats given i.v. ^{64}Zn-asp, t1 values at Day 36 were significantly lower as compared to those at Day 9 and Day 17, indicating improvement of remote spatial learning and memory.

The improvement of cognitive flexibility in the remote period after the first training session was observed in intact and sham-operated groups: t2 values at day 17 were significantly lower than those at the Day 9 (Fig.5I, K). Unexpectedly, at Day 36 (after the second training session), t2 values in these groups returned to the level at the Day 9 (Fig.5L), indicating that experience doesn't enhance remote cognitive flexibility in aged rats. In animals from AD group, cognitive flexibility in the remote period after retraining was significantly impaired: t2 median values at Day 36 were about 3 times higher than those at Day 9 and Day 17. Treatment with ^{64}Zn-asp tended to a minor improvement of remote cognitive flexibility after retraining in AD rats.

Given the close link that exists between inflammation and cognitive impairment according to literature data [66, 67], we performed correlation analysis of the relationship between biomarkers of local and systemic inflammation and cognitive characteristics in animals with AD (Table 4).

Table 4.

Correlations between cognitive parameters and biomarkers of local and systemic inflammation in rats with Aβ_{1-40}-induced Alzheimer disease

	Short-term spatial learning/memory		Short-term cognitive flexibility		Remote spatial learning/memory			Remote cognitive flexibility	
	$t1_{32}$	$t1$ Δ_{5-32}	$t2_{32}$	$t2$ Δ_{5-32}	$t1_{36}$	$t1$ Δ_{9-17}	$t1$ Δ_{9-36}	$t2$ Δ_{9-36}	$t2$ Δ_{17-36}
MG/BAM characteristics									
PP, %	0.79	-0.53		-0.43	0.73		-0.52		
PI, MFI	0.76	-0.88		-0.41					
ROS, MFI	0.79			-0.49	0.85		-0.63		
CD86+, %								-0.46	
CD86, MFI	0.93	-0.71	0.43	-0.65	0.59				
CD206+, %	0.56				0.62		-0.46		
CD206, MFI	0.69		0.42	-0.55	0.84	-0.41	-0.63		
Systemic inflammation markers									
Gr, x 10^3/μl	0.93	-0.71		-0.65	0.62				
Mo, x 10^3/μl	-0.61	0.42			-0.41				
Ly, x 10^3/μl									
Gr, %	0.95	-0.70		-0.64	0.64				
Mo, %	-0.90	0.59		0.75	-0.48				
Ly, %	-0.95	0.71		0.60	-0.67				
NLR	0.93			-0.67	0.67		-0.41		
SII	0.84			-0.62					
PNR	0.93			-0.65	0.62		-0.49		
NMR	0.93			-0.67	0.64				
AICD indicators									
Hgb, g/dl	0.88		0.56	-0.67	0.86	-0.43	-0.68	-0.47	-0.53
MCH, pg	0.90		0.49	-0.74	0.61				
MCHC, g/dl	0.91		0.43	-0.70	0.70		-0.46		

Note: Red shading in cells indicates very strong correlation, blue - strong, green – moderate. t1, escape latency - the time required for the animal to find the entrance to the target escape box from when the animal is released from the starting cylinder (characterizes spatial learning and spatial memory - related to the function of the hippocampus); t2, the time spent near the entrance to closed target hole (characterizes cognitive flexibility - related to the function of the frontal cortex of the brain). MCH, mean corpuscular hemoglobin; MCHC, concentration of hemoglobin in red blood cells; MFI, mean fluorescence intensity; NLR, neutrophil to lymphocyte ratio; NMR, neutrophil to monocyte ratio; PI, phagocytosis index; PLR, platelet to lymphocyte ratio; PNR, platelet to neutrophil ratio; PP, phagocytosis percentage; ROS, reactive oxygen species; SII, systemic immune inflammation index.

The highest number of positive strong and very strong correlations [68] was registered between inflammatory biomarkers and measure of the working memory $t1_{32}$. High values of this

measure, which indicate deterioration of spatial learning and formation of short-term or working spatial memory, strongly correlated with markers of systemic inflammation (absolute and relative Gr count, relative Mo and Ly count, as well as values if systemic inflammation indices) and AICD, and quite strongly - with markers of pro-inflammatory MG/BAM activation (increased proportion of phagocytizing cells, high phagocytic activity and ROS generation as well as high level of CD86 and CD206 expression). This suggests that reducing local and systemic inflammation in rats with AD receiving i.v. ^{64}Zn-asp, which was evidenced by normalizing the values of aforementioned biomarkers, can be one of the mechanisms of positive impact of the drug on working memory in lesioned animals.

Surprisingly, a measure of short-term cognitive flexibility $t2\Delta_{5-32}$ were more strongly correlated with biomarkers of systemic inflammation (absolute and relative Gr count, relative Mo and Ly count, as well as values if systemic inflammation indices), especially with AICD markers as compared with those of pro-inflammatory MG/BAM shift. This may indicate that counteracting the development of systemic inflammation and AICD can be one of the mechanisms of positive impact of ^{64}Zn-asp i.v.administration on short-term cognitive flexibility in AD rats.

Measures of long-term or remote spatial learning/memory generally had weaker correlation with biomarkers of neuro- and systemic inflammation as compared to those of short-term learning/memory. Strongest correlation of $t1_{36}$ values, which indicate the ability of animals to improve spatial memory after retraining, was observed with MG/BAM ROS generation and CD206 expression level, as well as with Hb concentration values. Moderate correlation prevailed between the measure of remote spatial learning and memory formation $t1\Delta_{9-36}$ and biomarkers of local and systemic inflammation. Close relationships with this parameter were registered only for MG/BAM ROS generation and CD86 expression level, as well as for Hb concentration: r values -0.63, -0.63 and -0.68 respectively. This indicates that pro-inflammatory MG/BAM metabolic shift with increased ROS production interferes with formation of remote spatial memory after retraining. Reducing pro-inflammatory MG/BAM shift by the i.v. treatment with ^{64}Zn-asp can be one of the mechanisms preventing deterioration of spatial learning ability in lesioned rats.

Surprisingly, the highest number of correlations with spatial learning/memory was registered for Hb concentration among all biomarkers of inflammation. This emphasize newly described role of Hb in the AD pathogenesis, and suggests that decrease of plasma Hb level (as a component of systemic inflammation) in rats with AD given i.v. ^{64}Zn-asp can be one of the mechanisms of positive drug effect on cognitive parameters in lesioned animals.

Parameters of long-term (remote) cognitive flexibility virtually were not correlated with markers of neuro- and systemic inflammation.

Discussion

In this study, $A\beta_{1-40}$-induced AD model was used for assessing impact of i.v. administration with ^{64}Zn-asp on local and systemic inflammation, and cognitive parameters in rats. This model was selected because of three main reasons. First, unlike $A\beta_{1-42}$, whose accumulation is inherent for early onset familial AD, $A\beta_{1-40}$ deposition is characteristic for late-onset AD, which is currently more common in the aging population worldwide, and it is these oligomers that prevail in the brain, blood vessels, and other tissues in patients with sporadic AD [69]. Second, since behavioral and pathological phenomena of AD, including neuro- and systemic inflammation are observed following $A\beta_{1-40}$ injection into the hippocampus, the $A\beta_{1-40}$ -induced model is generally regarded as an efficient model of AD [70, 45]. Third, synaptic zinc has more impact on $A\beta_{1-40}$ as compared to $A\beta_{1-42}$ [20].

The bioavailability and functional outcomes of zinc can be influenced by the form of Zn compound used. Zinc supplements progressed from inorganic to organic forms, partially, due to one of the key disadvantages of inorganic zinc agents: low bioavailability [71]. Different from zinc supplements, the ^{64}Zn-asp used in this study uses light isotope ^{64}Zn enriched to exceed 99%, which appears to allow the amplification of known anti-inflammatory features of zinc by the isotope effects (ref. 2020). Additionally, the ^{64}Zn-asp used in this study has another advantage, since the chelate

complex Zn^{2+} with aspartic acid was shown to possess allogenic suppressive activity indicating the prospects for it using to control inflammatory immune responses [72].

In our experiments, the i.v. administration of ^{64}Zn-asp have had potent inhibitory effect on neuroinflammation in rats with AD, since metabolic profile of complex MG/BAM population in AD rats received preparation was almost the same as that of control animals unlike pro-inflammatory shifted in untreated AD rats. Namely, ^{64}Zn-asp administration was accompanied by decrease of phagocytizing MG/BAM cell proportion and *S.aureus* phagocytosis intensity. *S. aureus* sensing and phagocytosis by MG/BAM cells involve nuclear factor kappa B (NF-κB) activation [73]. Increased NF-κB-dependent phagocytic activity, which was observed in rats with AD, is a marker of pro-inflammatory MG/BAM metabolic shift [56]. Zinc in known to impede NF-κB signaling [74], that can be one of the mechanisms of the inhibitory effect of ^{64}Zn-asp administration on MG/BAM phagocytic activity in rats with AD. Decreased phagocytic activity in turn was strongly correlated with improvement of short-term and remote spatial learning/memory. Increased ROS generation is one of the key hallmarks of so-called disease-associated microglia (DAM) in neurodegenerative diseases including AD [75]. Zinc in known for its antioxidant properties, which include inducing the expression of metallothioneins, activation of antioxidant proteins and enzymes etc. [74]. Oral zinc supplementation was shown is accompanied by alleviating oxidative stress in inflammatory condition [76, 77]. In our experiments, decreased ROS generation in rats with AD received i.v. ^{64}Zn-asp administration was also strongly correlated with improvement of short-term and remote spatial learning/memory. Elevated level of ROS generation is one of the potential molecular factors causing DN loss [78]. In addition, inflammatory mediators decrease release of dopamine [79]. Improvement of indicators for DN measuring observed in our study can be explained by alleviating neuroinflammation including decrease levels of inflammatory mediators such as ROS.

Levels of CD86 (or B7–2 - co-stimulatory receptor responsible for antigen presentation and T-cell activation) are upregulated in pro-inflammatory activated M1 MG [56], the same applies to BAM [80]. Zinc was shown to down-regulate co-stimulatory molecule expression and promotes tolerogenic phenotype in antigen-presenting cells [81, 82]. In rats with AD given the ^{64}Zn-asp, decreased CD86 expression level in MG/BAM, which indicate anti-inflammatory cell shift, was strongly correlated not only with spatial learning/memory improvement but also with enhancement of cognitive flexibility. The same goes for CD206 expression level, which is the marker of reactive MG and pro-inflammatory shifted BAM [58].

Neuroinflammation coupled with vascular pathology in AD are accompanied by blood-brain barrier weakening and outflowing inflammatory mediators into the periphery with developing systemic inflammation [83, 84]. In addition, AD in human unavoidably entails modifications of the hematopoietic system and hematopoietic maladaptation, which seems to be reproduced in the $Aβ_{1-40}$-induced AD model [85, 45]. In our experiments, three sets of signs prove the systemic inflammation phenomenon exists in rats with $Aβ_{1-40}$-induced AD. First, deviations from the norm of routine hematological parameters: absolute and relative neutrophilia, relative lymphopenia, absolute and relative monocytopenia. Second, substantially increased values of indices of systemic inflammation, and third, the presence of ACID. In animals with AD received i.v. ^{64}Zn-asp administration, the blood formula measures normalized. In the inflammatory conditions, dietary zinc supplementation or administration by injection could reduce the enrollment and activity of Neu, in such a way ameliorating inflammation and tissue damage [86, 87]. In our experiments, reduced systemic inflammation in rats with AD given the i.v. ^{64}Zn-asp was correlated with short-term spatial learning/memory improvement, and quite strongly - with enhancement of short-term cognitive lability. Therefore, ^{64}Zn-asp effects that lower systemic inflammation, could be considered as one of the mechanisms of improvement of measures of short-term memory and cognitive flexibility. Our findings are consistent with data of de Vargas et al. [88], which observed anti-inflammatory effects of zinc supplementation in overweight or obese women coupled with enhance cognitive health.

The reduction of AICD manifestations in rats with AD after the i.v. ^{64}Zn-asp administration deserves special attention due to correlation with improved cognitive performance measures.

Particularly, free Hg serum level, in rats with AD given the i.v. ^{64}Zn-asp, were strongly correlated with cognitive improvements. Both low and high Hb serum levels are associated with an increased risk of dementia, including AD, which may relate to differences in white matter integrity and cerebral perfusion [89]. In addition, extracellular Hb released from destroyed RBC may cause neurotoxicity and neurodegeneration, as well as the BBB weakening in AD [90, 91]. In addition to well-known stimulatory impact to erythropoiesis [92], zinc possess cytoprotective activity through stabilizing membrane proteins [93], and decrease RBC osmotic fragility [94]. That might explain positive impact of i.v. ^{64}Zn-asp administration in animals with AD on serum level of free Hb as well as on other RBC measures which were correlated with cognitive improvements.

Despite a significant improvement in long-term (remote) spatial learning/memory and slight improvement in remote cognitive flexibility in rats with AD given the i.v. ^{64}Zn-asp as compared with untreated rats, we did not observe strong correlations between measures of remote cognitive activity and markers of neuro- and systemic inflammation. Perhaps the reason lies in different vulnerability of neurons from distinct brain parts to inflammatory mediators [95]. Right posterior parietal cortex and the right lateral prefrontal cortex are responsible for the processing of spatial working memory. Right medial temporal lobe, including the hippocampus, are implicated in long-term spatial memory, although hippocampus is always necessary to retrieve spatial information [96]. The lack of correlation between these cognitive measures and inflammatory markers could reflect the contribution of processes other than inflammation to cognitive impairment. Therefore, another reason for the absence of correlation between improvements in measures of remote spatial memory and inflammatory markers in rats with AD given ^{64}Zn-asp could be direct impact of the drug on neuron functions, which was not investigated in our experiments and requires separate study.

Conclusion

In summary, local, and systemic inflammation is considered as an important component of AD pathogenesis. Therefore, the search for drugs to counteract with inflammatory processes in AD is highly relevant, considering global prevalence of the disease. In our study, Aβ_{1-40}-induced AD in rats was associated with pronounce neuroinflammation, as ascertained by pro-inflammatory metabolic shift of MG/BAM cells, as well as with persistent systemic inflammation, which manifested by sharply increased values of WBC-based inflammatory biomarkers and AICD development. The findings of our study indicate that i.v. ^{64}Zn-asp administration led to potent inhibition of both neuro- and systemic inflammation, that confer a beneficial impact on cognition in lesioned animals. However, it is necessary to point, that direct effect of ^{64}Zn-asp on zinc homeostasis and neuron functions were not evaluated in this study, which warrants future experiments. Despite this, the results of current study justify the prospects of using ^{64}Zn-asp to counteract with inflammation and improve cognition in AD.

Author Contribution
MT: supervision and writing - review and editing. MR: methodology, investigation, formal analysis. AB: methodology, conceptualization, and project administration. SG: conceptualization, writing - review and editing. TD: methodology, investigation. RB: methodology, conceptualization. ND: methodology, investigation. GT: supervision and writing - review and editing. LS: methodology, conceptualization, project administration and writing - original draft. All authors read the final version of the manuscript.

Data Availability

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Declarations

Competing Interests

The authors declare no competing interests.

References

1. Reiss AB, Pinkhasov A (2024) Special Issue "Commemorative Issue Celebrating the 20th Anniversary of the Alzheimer's Foundation of America: Understanding and Treating Alzheimer's Disease". Medicina (Kaunas) 60: 712. https://doi.org/10.3390/medicina60050712;
2. DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer's disease. Molecular neurodegeneration 14: 32. https://doi.org/10.1186/s13024-019-0333-5
3. 2024 Alzheimer's disease facts and figures. (2024). Alzheimers Dement 20:3708–3821. https://doi.org/10.1002/alz.13809;
4. Liu Y, Tan Y, Zhang Z, Yi M, Zhu L, Peng W (2024). The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing. Transl Neurodegener 13: 7. https://doi.org/10.1186/s40035-024-00397-x
5. Tomaskova H, Kuhnova J, Cimler R, Dolezal O, Kuca K (2016). Prediction of population with Alzheimer's disease in the European Union using a system dynamics model. Neuropsychiatr Dis Treat 12: 1589–1598. https://doi.org/10.2147/NDT.S107969
6. Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L (2024) Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9: 211. https://doi.org/10.1038/s41392-024-01911-3
7. Islam MR, Rabbi MA, Hossain T, Sultana S, Uddin S (2024) Mechanistic Approach to Immunity and Immunotherapy of Alzheimer's Disease: A Review. ACS Chem Neurosci, 10.1021/acschemneuro.4c00360. Advance online publication. https://doi.org/10.1021/acschemneuro.4c00360;
8. Sharo C, Zhai T, Huang Z (2024) Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer's Disease Progression. Pharmaceuticals (Basel)17: 137. https://doi.org/10.3390/ph17010137;
9. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM (2021) Donanemab in Early Alzheimer's Disease. N Engl J Med 384: 1691–1704. https://doi.org/10.1056/NEJMoa2100708
10. Gyimesi M, Okolicsanyi RK, Haupt LM (2024) Beyond amyloid and tau: rethinking Alzheimer's disease through less explored avenues. Open Biol 14: 240035. https://doi.org/10.1098/rsob.240035
11. Roy RG, Mandal PK, Maroon JC (2023) Oxidative Stress Occurs Prior to Amyloid Aβ Plaque Formation and Tau Phosphorylation in Alzheimer's Disease: Role of Glutathione and Metal Ions. ACS Chem Neurosci 14: 2944–2954. https://doi.org/10.1021/acschemneuro.3c00486
12. Kalaria RN (2016) Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease. Acta Neuropathol 131: 659–685. https://doi.org/10.1007/s00401-016-1571-z

13. Wiatrak B, Jawień P, Szeląg A, Jęśkowiak-Kossakowska I (2023) Does Inflammation Play a Major Role in the Pathogenesis of Alzheimer's Disease? Neuromolecular Med 25(3): 330–335. https://doi.org/10.1007/s12017-023-08741-6;

14. Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y) 4: 575–590. https://doi.org/10.1016/j.trci.2018.06.014

15. Perry VH, Teeling J (2013). Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol 5: 601–612. https://doi.org/10.1007/s00281-013-0382-8

16. Wu S, Chen N, Wang C (2024) Frontiers and hotspots evolution in anti-inflammatory studies for Alzheimer's disease. Behav Brain Res 472: 115178. https://doi.org/10.1016/j.bbr.2024.115178

17. Galloway P, McMillan DC, Sattar N (2000) Effect of the inflammatory response on trace element and vitamin status. Ann Clin Biochem 37: 289–297. https://doi.org/10.1258/0004563001899429

18. Portbury SD, Adlard PA (2017) Zinc Signal in Brain Diseases. Int J Mol Sci 18: 2506. https://doi.org/10.3390/ijms18122506

19. Coudray C, Feillet-Coudray C, Rambeau M, Tressol JC, Gueux E, Mazur A, Rayssiguier Y (2006) The effect of aging on intestinal absorption and status of calcium, magnesium, zinc, and copper in rats: a stable isotope study. J Trace Elem Med Biol 20: 73–81. https://doi.org/10.1016/j.jtemb.2005.10.007

20. Xie Z, Wu H, Zhao J (2020) Multifunctional roles of zinc in Alzheimer's disease. Neurotoxicology 80: 112–123. https://doi.org/10.1016/j.neuro.2020.07.003

21. Craddock TJ, Tuszynski JA, Chopra D, Casey N, Goldstein LE, Hameroff SR, Tanzi RE (2012) The zinc dyshomeostasis hypothesis of Alzheimer's disease. PLoS One 7: e33552. https://doi.org/10.1371/journal.pone.0033552

22. Kim JW, Byun MS, Yi D, Lee JH, Kim MJ, Jung G, Lee JY, Kang KM, Sohn CH, Lee YS, Kim YK, Lee DY, KBASE Research Group (2021) Serum zinc levels and in vivo beta-amyloid deposition in the human brain. Alzheimers Res Ther 13: 190. https://doi.org/10.1186/s13195-021-00931-3

23. González C, Martín T, Cacho J, Breñas MT, Arroyo T, García-Berrocal B, Navajo JA, González-Buitrago JM (1999) Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 29: 637–642. https://doi.org/10.1046/j.1365-2362.1999.00471.x

24. Shippy DC, Oliai SF, Ulland TK (2024) Zinc utilization by microglia in Alzheimer's disease. J Biol Chem 300: 107306. https://doi.org/10.1016/j.jbc.2024.107306

25. Panayi AE, Spyrou NM, Iversen BS, White MA, Part P (2002) Determination of cadmium and zinc in Alzheimer's brain tissue using inductively coupled plasma mass spectrometry. J Neurol Sci 195: 1–10. https://doi.org/10.1016/s0022-510x(01)00672-4

26. Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, Naslund J, Bush AI (2006) Elevated cortical zinc in Alzheimer disease. Neurology 67: 69–75. https://doi.org/10.1212/01.wnl.0000223644.08653.b5

27. Li Q, Barres BA (2018) Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol 18: 225–242. https://doi.org/10.1038/nri.2017.125

28. Kaur SKM, Sharma A, Giridharan VV, Dandekar MP (2024) Brain resident microglia in Alzheimer's disease: foe or friends. Inflammopharmacology 10.1007/s10787-024-01550-8. Advance online publication. https://doi.org/10.1007/s10787-024-01550-8

29. Higashi Y, Aratake T, Shimizu T, Shimizu S, Saito M (2022) Role of zinc in microglial phenotypes. Metallomics Research 2: 54-63. https://doi.org/10.11299/metallomicsresearch.MR202116;

30. Wang Y, Song Y, Zhang L, Huang X (2024) The paradoxical role of zinc on microglia. J Trace Elem Med Biol 83: 127380. https://doi.org/10.1016/j.jtemb.2023.127380

31. Brewer GJ (2012) Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease. Biofactors 38: 107–113. https://doi.org/10.1002/biof.1005;

32. Squitti R, Pal A, Picozza M, Avan A, Ventriglia M, Rongioletti MC, Hoogenraad T (2020) Zinc Therapy in Early Alzheimer's Disease: Safety and Potential Therapeutic Efficacy. Biomolecules 10: 1164. https://doi.org/10.3390/biom10081164

33. Jaouen K, Pouilloux L, Balter V, Pons ML, Hublin JJ, Albarède F (2019) Dynamic homeostasis modeling of Zn isotope ratios in the human body. Metallomics 11: 1049-1059. https://doi.org/10.1039/c8mt00286j

34. Tanaka YK, Hirata T (2018) Stable Isotope Composition of Metal Elements in Biological Samples as Tracers for Element Metabolism. Anal Sci 34: 645-655. https://doi.org/10.2116/analsci.18SBR02;

35. Solovyev N, El-Khatib AH, Costas-Rodríguez M, Schwab K, Griffin E, Raab A, Platt B, Theuring F, Vogl J, Vanhaecke F (2021) Cu, Fe, and Zn isotope ratios in murine Alzheimer's disease models suggest specific signatures of amyloidogenesis and tauopathy. J Biol Chem 296:100292. https://doi.org/10.1016/j.jbc.2021.100292

36. Albarede F, Télouk P, Balter V, Bondanese VP, Albalat E, Oger P, Bonaventura P, Miossec P, Fujii T (2016) Medical applications of Cu, Zn, and S isotope effects. Metallomics 8:1056-1070. https://doi.org/10.1039/c5mt00316d

37. Moynier F, Borgne ML, Lahoud E, Mahan B, Mouton-Liger F, Hugon J, Paquet C (2020) Copper and zinc isotopic excursions in the human brain affected by Alzheimer's disease. Alzheimers Dement (Amst) 12: e12112. https://doi.org/10.1002/dad2.12112

38. Novak P, Balakin A, Temnik M (2022) In Vitro Anticancer Activity of the Light Stable Zinc Isotope (^{64}Zn) Compounds. Anticancer Res 42:5685-5698. https://doi.org/10.21873/anticanres.16077

39. Novak P, Temnikov M, Balakin O (2022)US20200000845A1 - Pharmaceutical Composition for Improving Health, Cure Abnormalities and Degenerative Disease, Achieve Anti-Aging Effect of Therapy and Therapeutic Effect on Mammals and Method Thereof - Google Patents https://patents.google.com/patent/US20200000845A1/en

40. Cvijanovich NZ, King JC, Flori HR, Gildengorin G, Vinks AA, Wong HR (2016) Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness. JPEN J Parenter Enteral Nutr 40:860–868. https://doi.org/10.1177/0148607115572193;

41. Baltaci SB, Gümüş H, Ünal Ö, Acar G, Bayiroğlu AF (2024) Zinc Supplementation Improves ZIP14 (SLC39A14) Levels in Cerebral Cortex Suppressed by icv-STZ Injection. Noro Psikiyatr Ars 61:11–14. https://doi.org/10.29399/npa.28426;

42. Gumus H, Baltaci SB, Unal O, Gulbahce-Mutlu E, Mogulkoc R, Baltaci AK (2023) Zinc Ameliorates Nogo-A Receptor and Osteocalcin Gene Expression in Memory-Sensitive Rat Hippocampus Impaired by Intracerebroventricular Injection of Streptozotocin. Biol Trace Elem Res 201: 3381–3386. https://doi.org/10.1007/s12011-022-03410-4

43. Shi X, Lu X, Zhan L, Liu L, Sun M, Gong X, Sui H, Niu X, Liu S, Zheng L, Chen J, Zhou Y, (2011) Rat hippocampal proteomic alterations following intrahippocampal injection of amyloid beta peptide (1–40). Neurosci Lett 500:87–91. https://doi.org/10.1016/j.neulet.2011.06.009;

44. Berchenko OG, Levicheva NO, Bevzyuk DO, Sokolik VV (2020) The effect of miR-101 on the memory of rats with a model of Alzheimer's disease. Regul Mech Biosyst 11:354-359. https://doi.org/10.15421/022054;

45. Nefodova A, Rudyk M, Dovhyi R, Dovbynchuk T, Dzubenko N, Tolstanova G, Skivka L (2024) Systemic inflammation in Aβ1-40-induced Alzheimer's disease model: New translational opportunities. Brain Res 1837:148960. https://doi.org/10.1016/j.brainres.2024.148960

46. Gholipour P, Komaki A, Parsa H, Ramezani M (2022) Therapeutic Effects of High-Intensity Interval Training Exercise Alone and Its Combination with Ecdysterone Against Amyloid Beta-Induced Rat Model of Alzheimer's Disease: A Behavioral, Biochemical, and Histological Study. Neurochem Res 47:2090–2108. https://doi.org/10.1007/s11064-022-03603-2

47. Peris LR, Scheuber MI, Shan H, Braun MM, Schwab ME (2024) Barnes maze test for spatial memory: A new, sensitive scoring system for mouse search strategies. Behav Brain Res 458: 114730. https://doi.org/10.1016/j.bbr.2023.114730

48. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651–3664. https://doi.org/10.1200/JCO.2000.18.21.3651

49. Ou-Yang H, Fu HY, Luo Y, Xu ZY, Liu J, Gao R, Duan JY, Mao YC, Li HJ, Du YR (2023) Inflammation markers and the risk of hypertension in people living with HIV. Front Immunol 14:1133640. https://doi.org/10.3389/fimmu.2023.1133640

50. Frank MG, Wieseler-Frank JL, Watkins LR, Maier SF (2006) Rapid isolation of highly enriched and quiescent microglia from adult rat hippocampus: immunophenotypic and functional characteristics. J Neurosci Methods 151:121–130. https://doi.org/10.1016/j.jneumeth.2005.06.026;

51. Oliynyk Z, Rudyk M, Dovbynchuk T, Dzubenko N, Tolstanova G, Skivka L (2023) Inflammatory hallmarks in 6-OHDA- and LPS-induced Parkinson's disease in rats. Brain Behav Immun Health 30:100616. https://doi.org/10.1016/j.bbih.2023.100616

52. Mishra P, Pandey CK, Singh U, Gupta A, Sahu C, Keshri A (2019) Descriptive statistics and normality tests for statistical data. Ann Card Anaesth 22:67-72. https://doi.org/10.4103/aca.aca_157_18

53. Chan YL, Walmsley R (1997) Learning and understanding the Kruskal-Wallis One-Way Analysis-of-Variance-by-Ranks Test for differences among three or more independent groups. Phys Ther 77: 1755–1761. https://doi.org/10.1093/ptj/77.12.1755

54. Dermitzakis I, Theotokis P, Evangelidis P, Delilampou E, Evangelidis N, Chatzisavvidou A, Avramidou E, Manthou ME (2023) CNS Border-Associated Macrophages: Ontogeny and Potential Implication in Disease. Curr Issues Mol Biol 45:4285–4300. https://doi.org/10.3390/cimb45050272

55. Silvin A, Qian J, Ginhoux F (2023) Brain macrophage development, diversity and dysregulation in health and disease. Cell Mol Immunol 20:1277-1289. https://doi.org/10.1038/s41423-023-01053-6

56. Jurga AM, Paleczna M, Kuter KZ (2020) Overview of General and Discriminating Markers of Differential Microglia Phenotypes. Front Cell Neurosci 14:198. https://doi.org/10.3389/fncel.2020.00198

57. Sun R, Jiang H (2024) Border-associated macrophages in the central nervous system. J Neuroinflammation 21:67. https://doi.org/10.1186/s12974-024-03059-x;

58. Wen W, Cheng J, Tang Y (2024) Brain perivascular macrophages: current understanding and future prospects. Brain 147:39–55. https://doi.org/10.1093/brain/awad304

59. Kolaczkowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13:159–175. https://doi.org/10.1038/nri3399

60. Kratofil RM, Kubes P, Deniset JF (2017) Monocyte Conversion During Inflammation and Injury. Arterioscler Thromb Vasc Biol 37:35–42. https://doi.org/10.1161/ATVBAHA.116.308198;

61. Orozco SL, Canny SP, Hamerman JA (2021) Signals governing monocyte differentiation during inflammation. Curr Opin Immunol 73:16–24. https://doi.org/10.1016/j.coi.2021.07.007

62. Ludwig N, Hilger A, Zarbock A, Rossaint J (2022) Platelets at the Crossroads of Pro-Inflammatory and Resolution Pathways during Inflammation. Cells 11:1957. https://doi.org/10.3390/cells11121957

63. Margraf A, Zarbock A (2019) Platelets in Inflammation and Resolution. J Immunol 203:2357–2367. https://doi.org/10.4049/jimmunol.1900899

64. Andreev A, Erdinc B, Shivaraj K, Schmutz J, Levochkina O, Bhowmik D, Farag F, Money KM, Primavera LH, Gotlieb V, Sahni S (2020) The Association Between Anemia of Chronic Inflammation and Alzheimer's Disease and Related Dementias. J Alzheimers Dis Rep 4:379–391. https://doi.org/10.3233/ADR-200178

65. White RB, Thomas MG (2012) Moving beyond tyrosine hydroxylase to define dopaminergic neurons for use in cell replacement therapies for Parkinson's disease. CNS Neurol Disord Drug Targets 11:340–349. https://doi.org/10.2174/187152712800792758

66. Schmidt-Morgenroth I, Michaud P, Gasparini F, Avrameas A (2023) Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's Disease. Int J Mol Sci, 24:10523. https://doi.org/10.3390/ijms241310523;

67. Appleton J, Finn Q, Zanotti-Fregonara P, Yu M, Faridar A, Nakawah MO, Zarate C, Carrillo M, Dickerson BC, Rabinovici G, Apostolova LG, Masdeu JC, Pascual B (2024) Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer's disease. Brain. https://doi.org/10.1093/brain/awae234

68. Papageorgiou SN (2022) On correlation coefficients and their interpretation. Journal of orthodontics 49:359–361. https://doi.org/10.1177/14653125221076142

69. Zou P, Ding Y, Sha Y, Hu B, Nie S (2003) Humanin peptides block calcium influx of rat hippocampal neurons by altering fibrogenesis of Abeta(1-40). Peptides 24:679–685. https://doi.org/10.1016/s0196-9781(03)00131-1

70. Park J, Lee SY, Shon J, Kim K, Lee HJ, Kim KA, Lee BY, Oh SH, Kim NK, Kim OJ (2019) Adalimumab improves cognitive impairment, exerts neuroprotective effects and attenuates neuroinflammation in an $A\beta_{1-40}$-injected mouse model of Alzheimer's disease. Cytotherapy 21:671–682. https://doi.org/10.1016/j.jcyt.2019.04.054;

71. Liu S, Wang N, Long Y, Wu Z, Zhou S (2023) Zinc Homeostasis: An Emerging Therapeutic Target for Neuroinflammation Related Diseases. Biomolecules 13:416. https://doi.org/10.3390/biom13030416

72. Piacenza F, Giacconi R, Costarelli L, Malavolta M (2023) Preliminary Comparison of Fractional Absorption of Zinc Sulphate, Zinc Gluconate, and Zinc Aspartate after Oral Supplementation in Healthy Human Volunteers. Nutrients 15:1885. https://doi.org/10.3390/nu15081885

73. Zhu F, Yue W, Wang Y (2014) The nuclear factor kappa B (NF-κB) activation is required for phagocytosis of staphylococcus aureus by RAW 264.7 cells. Exp Cell Res 327:256–263. https://doi.org/10.1016/j.yexcr.2014.04.018

74. Jarosz M, Olbert M, Wyszogrodzka G, Młyniec K, Librowski T (2017) Antioxidant and anti-inflammatory effects of zinc. Zinc-dependent NF-κB signaling. Inflammopharmacology 25:11–24. https://doi.org/10.1007/s10787-017-0309-4

75. Simpson DSA, Oliver PL (2020) ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease. Antioxidants (Basel) 9:743. https://doi.org/10.3390/antiox9080743

76. Sun X, Xu S, Liu T, Wu J, Yang J, Gao XJ (2024) Zinc supplementation alleviates oxidative stress to inhibit chronic gastritis via the ROS/NF-κB pathway in a mouse model. Food Funct 15:7136–7147. https://doi.org/10.1039/d4fo01142b;

77. Mohammadi H, Talebi S, Ghavami A, Rafiei M, Sharifi S, Faghihimani Z, Ranjbar G, Miraghajani M, Askari G (2021) Effects of zinc supplementation on inflammatory biomarkers and oxidative stress in adults: A systematic review and meta-analysis of randomized controlled trials. J Trace Elem Med Biol 68:126857. https://doi.org/10.1016/j.jtemb.2021.126857

78. Delcambre S, Nonnenmacher Y, Hiller K (2016) Dopamine Metabolism and Reactive Oxygen Species Production. In: Buhlman, L. (eds) Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. Springer, Cham, pp 25-47. https://doi.org/10.1007/978-3-319-42139-1_2

79. Bekhbat M, Li Z, Mehta ND, Treadway MT, Lucido MJ, Woolwine BJ, Haroon E, Miller AH, Felger JC (2022) Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Mol Psychiatry 27:4113–4121. https://doi.org/10.1038/s41380-022-01715-3

80. Gerganova G, Riddell A, Miller AA (2022) CNS border-associated macrophages in the homeostatic and ischaemic brain. Pharmacol Ther 240:108220. https://doi.org/10.1016/j.pharmthera.2022.108220

81. Hojyo S, Fukada T (2016) Roles of Zinc Signaling in the Immune System. J Immunol Res 2016:6762343. https://doi.org/10.1155/2016/6762343;

82. George MM, Subramanian Vignesh K, Landero Figueroa JA, Caruso JA, Deepe GS Jr (2016) Zinc Induces Dendritic Cell Tolerogenic Phenotype and Skews Regulatory T Cell-Th17 Balance. J Immunol 197:1864–1876. https://doi.org/10.4049/jimmunol.1600410

83. Cao W, Zheng H (2018) Peripheral immune system in aging and Alzheimer's disease. Mol Neurodegener 13:51. https://doi.org/10.1186/s13024-018-0284-2;

84. Chen T, Dai Y, Hu C, Lin Z, Wang S, Yang J, Zeng L, Li S, Li W (2024) Cellular and molecular mechanisms of the blood-brain barrier dysfunction in neurodegenerative diseases. Fluids Barriers CNS 21:60. https://doi.org/10.1186/s12987-024-00557-1

85. Naert G, Rivest S (2013) A deficiency in CCR2+ monocytes: the hidden side of Alzheimer's disease. J Mol Cell Biol 5:284–293. https://doi.org/10.1093/jmcb/mjt028

86. Shao YR, Xu DY, Lin J (2023) Nutrients and rheumatoid arthritis: From the perspective of neutrophils. Front Immunol 14:1113607. https://doi.org/10.3389/fimmu.2023.1113607;

87. Lay CSV, Fasitasari M, Christianto F, Puruhita N, Probosari E, Murbawani EA (2024) Dietary zinc intake and absolute lymphocyte counts in advanced stage of nasopharyngeal cancer patients. Hum Nutr Metab 36:200261. https://doi.org/10.1016/j.hnm.2024.200261

88. de Vargas LDS, Jantsch J, Fontoura JR, Dorneles GP, Peres A, Guedes RP (2023) Effects of Zinc Supplementation on Inflammatory and Cognitive Parameters in Middle-Aged Women with Overweight or Obesity. Nutrients 15:4396. https://doi.org/10.3390/nu15204396

89. Wolters FJ, Zonneveld HI, Licher S, Cremers LGM, Heart Brain Connection Collaborative Research Group, Ikram MK, Koudstaal PJ, Vernooij MW, Ikram MA (2019) Hemoglobin and anemia in relation to dementia risk and accompanying changes on brain MRI. Neurology 93:e917–e926. https://doi.org/10.1212/WNL.0000000000008003

90. Drvenica IT, Stančić AZ, Maslovarić IS, Trivanović DI, Ilić VL (2022) Extracellular Hemoglobin: Modulation of Cellular Functions and Pathophysiological Effects. Biomolecules 12:1708. https://doi.org/10.3390/biom12111708;

91. Altinoz MA, Guloksuz S, Schmidt-Kastner R, Kenis G, Ince B, Rutten BPF (2019) Involvement of hemoglobins in the pathophysiology of Alzheimer's disease. Exp Gerontol 126:110680. https://doi.org/10.1016/j.exger.2019.110680

92. Takahashi A (2024) Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors. Nutrients 16:520. https://doi.org/10.3390/nu16040520

93. Perera M, Ischia J, Bolton D, Shulkes A, Baldwin GS, Patel O (2021) Zinc Preconditioning Provides Cytoprotection following Iodinated Contrast Media Exposure in In Vitro Models. Contrast Media Mol Imaging 2021:6686803. https://doi.org/10.1155/2021/6686803

94. Candan F, Gültekin F, Candan F (2002) Effect of vitamin C and zinc on osmotic fragility and lipid peroxidation in zinc-deficient haemodialysis patients. Cell Biochem Funct 20:95–98. https://doi.org/10.1002/cbf.947

95. Wang X, Michaelis ML, Michaelis EK (2010) Functional genomics of brain aging and Alzheimer's disease: focus on selective neuronal vulnerability. Curr Genomics 11:618–633. https://doi.org/10.2174/138920210793360943

96. Zorzo C, Arias JL, Méndez M (2022) Functional neuroanatomy of allocentric remote spatial memory in rodents. Neurosci Biobehav Rev 136:104609. https://doi.org/10.1016/j.neubiorev.2022.104609